Thermo Fisher Q3 2026 Results Raise Outlook

Thermo Fisher Scientific (TMO) reported third-quarter 2026 results on Oct. 21, showing stronger revenue and margin performance. The company raised its full-year revenue, adjusted earnings per share (EPS), organic-growth, and free-cash-flow outlooks amid improving pharmaceutical and industrial demand.

Quarter Results and Margins

Thermo Fisher posted third-quarter revenue of $12.14 billion, a 9% increase year over year, with 6% organic growth excluding acquisitions, divestitures, and currency effects. Adjusted EPS rose 15% to $6.68, while adjusted operating income increased 15% to $2.97 billion. Adjusted operating margin expanded 120 basis points to 24.5%. On a GAAP basis, diluted EPS climbed 9% to $4.64, and GAAP operating income rose 17% to $2.26 billion, pushing the GAAP operating margin to 18.6% from 17.4% a year earlier.

By segment, Laboratory Products and Biopharma Services led growth with revenue up 15% to $6.86 billion, segment income of $1.07 billion, and margin expansion to 15.5% from 14.5%. Life Sciences Solutions revenue increased 5.1% to $2.72 billion, with segment income of $1.02 billion and a 37.6% margin. Analytical Instruments revenue rose 5.8% to about $2.0 billion, lifting segment income to $538 million and expanding margin to 26.9% from 22.6%.

Outlook, Cash Flow, and Capital Allocation

Management raised full-year 2026 revenue guidance to $47.7 billion–$48.2 billion, reflecting 7%–8% reported growth over 2025. Adjusted EPS guidance increased to $25.13–$25.43, representing 10%–11% growth. The company also raised organic revenue growth guidance to 4% and free-cash-flow guidance to $7.0 billion–$7.5 billion. It maintained an expectation of roughly 80 basis points of adjusted operating margin expansion for the year.

For the first nine months, operating cash flow reached $5.87 billion and free cash flow totaled $4.62 billion, compared with $4.36 billion and $3.32 billion in the same period of 2025. During this time, Thermo Fisher completed $8.88 billion of acquisitions net of cash acquired, repurchased $4.0 billion of shares, and paid $511 million in dividends. At quarter-end, the company held $5.46 billion in cash and cash equivalents and reported approximately $41.4 billion in total debt.

Company materials attributed the quarter’s strength to continued improvement in pharmaceutical and biotechnology activity, alongside strengthening industrial and applied-market demand. The company also completed a microbiology-business divestiture during the period.